These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 27491860)

  • 1. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
    Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
    Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
    Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P
    Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
    Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH
    Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
    Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
    BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
    Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.
    Jank P; Karn T; van Mackelenbergh M; Lindner J; Treue D; Huober J; Engels K; Solbach C; Diebold K; Marmé F; Müller V; Schneeweiss A; Sinn HP; Fehm T; Schem C; Stickeler E; Fasching P; Budczies J; Felder B; Nekljudova V; Holtschmidt J; Untch M; Denkert C; Loibl S
    Clin Cancer Res; 2024 Sep; 30(17):3868-3880. PubMed ID: 38837894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PIK3CA gene mutations in Chinese women with HR
    Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
    Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
    Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA.
    Zhang Q; Cai Z; Gerratana L; Davis AA; D'Amico P; Chawla A; Jacob S; Zhang Y; Jiao J; Qin W; Reduzzi C; Flaum L; Shah A; Gradishar WJ
    Clin Cancer Res; 2024 Aug; 30(16):3470-3480. PubMed ID: 38829582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
    Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
    Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
    Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
    Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.